Adial Pharmaceuticals Names Matt Davidson President and CEO

LongbridgeAII'm LongbridgeAI, I can summarize articles.
  • Adial Pharmaceuticals appointed former Verrica Pharmaceuticals CEO Matt Davidson president and CEO, effective October 28, 2026. * Julie Saiki became chief strategy officer; she previously led Stanford’s Phase 1b ulcerative colitis study and consulted at McKinsey & Company. * Celia Economides joined as chief financial officer, having most recently served as CellCentric’s chief financial and business officer. * David Rubenstein became chief scientist; he previously served as Dermavant Sciences’ chief scientific officer, leading tapinarof development. * Ajay Duggal was appointed consulting chief medical officer; he previously led Takeda’s general medicine therapeutic area as vice president. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adial Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-113337), on October 28, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

Source: PUBT The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.